Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous anifrolumab in adults with polymyositis or dermatomyositis
2023-504022-19-01Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in polymyositis (PM) and dermatomyositis (DM) comparing Anifrolumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Moderate improvement in disease activity without confirmed deterioration. Planned start Dec 2024; status: authorised.
02
Drugs
anifrolumab
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on 2023-504022-19-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504022-19-01.